News & Updates
Filter by Specialty:
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
05 Jun 2025
Insights from latest CCS & ACS guidelines on lipid management
The advent of new lipid-lowering agents, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has led to guideline updates on management of chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). In addition to potent LDL-cholesterol (LDL-C) reduction, alirocumab may mitigate atherosclerotic cardiovascular disease (ASCVD) risk by inducing plaque stabilization and exerting protective vascular effects.
Insights from latest CCS & ACS guidelines on lipid management
05 Jun 2025
Phase IIb study supports lorundrostat for treatment-resistant hypertension
The phase IIb Advance-HTN trial shows the blood pressure (BP)-lowering effect of lorundrostat in patients with uncontrolled and treatment-resistant hypertension (HTN).